ArticleJournal of the National Cancer Center2025
Divergent trends in the burden of esophageal, gastric, and liver cancers in China.
Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts.BMC gastroenterology · 2026Pooled it
- Trial
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer (ERSS-EGC): A study protocol for a randomized controlled trial.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- CLDN18.2 antibody design with protein language models: A deep learning optimization framework.PLoS computational biology · 2026Article
- Evaluating the prognostic value of cuproptosis-related genes and characterizing PDE3B's role in gastric cancer: integrative bioinformatics analysis and experimental validation.Journal of gastrointestinal oncology · 2026Article
- Constructing and investigating a disulfidptosis-associated LncRNA signature for prognostic prediction in gastric cancer.Discover oncology · 2026Article
- Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.Gastroenterology report · 2026Review
- Timeliness of postoperative serum carcinoembryonic antigen monitoring for predicting recurrence after gastric cancer surgery.World journal of gastrointestinal surgery · 2026Article
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
- Clonal evolution in gastrointestinal cancers: multi-omics insights into tumor heterogeneity, microenvironmental selection, and translational biomarkers.Frontiers in oncology · 2026Review
- Trends and future burden of major digestive system cancers in Jiangsu Province, China, 2010-2030.Frontiers in oncology · 2026Article
- Subnational situation and public awareness of cancer control in China.World journal of clinical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While China's socioeconomic transformation has driven divergent trends in gastrointestinal cancers, comprehensive data on esophageal, gastric, and liver cancer burden remain limited. This study examines the global burden of esophageal, gastric, and liver cancers in 2022 and analyzes the trends of age-standardized incidence and mortality rate (ASRs) in China from 2000 to 2018, thereby providing evidence for the formulation of cancer control strategies. Methods: The global burden of esophageal, gastric and liver cancers including the estimated number of cases and deaths and the ASRs for incidence and mortality were from GLOBALCAN 2022 dataset. Data from 22 cancer registries in China were employed for the trend analysis of the ASRs for incidence and mortality of these three cancers. The Joinpoint model was used to compute the average annual percentage change (AAPC) of the incidence and mortality of the three cancers from 2000 to 2018. Results: Globally, esophageal, gastric and liver cancers accounted for 11.8 % of incident cancer cases and 19.1 % of cancer deaths. China bore a disproportionately high burden, representing 43.8 %, 37.0 %, and 42.4 % of global esophageal, gastric, and liver cancer cases respectively, and 42.1 %, 39.4 %, and 41.7 % of corresponding deaths. However, the ASRs for incidence and mortality for all three cancers declined significantly in China (2000-2018), with absolute case numbers decreasing for gastric and esophageal cancers during 2010-2022. Age-specific analysis revealed most pronounced declines in incidence and mortality in populations under 40 years old, with AAPCs of less than -6.0 % for esophageal cancer, around -4.0 % for gastric cancer, and approximately -2.0 % for liver cancer. Conclusions: China has achieved remarkable progress in controlling esophageal, gastric and liver cancers, yet these malignancies remain major public health challenges. Future efforts should intensify existing prevention measures while expanding screening programs, particularly for aging populations. These findings offer valuable insights for regions undergoing similar epidemiological transitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.